The National Pregnancy Registry for Atypical Antipsychotics

If you are a pregnant woman between the ages of 18 and 45 and are currently treated with one or more of the following atypical antipsychotics:

- Abilify (aripiprazole)
- Clozaril (clozapine)
- Geodon (ziprasidone)
- Invega (paliperidone)
- Risperdal (risperidone)
- Seroquel (quetiapine)
- Zyprexa (olanzapine)
- Saphris (asenapine)
- Fanapt (iloperidone)
- Latuda (lurasidone)

Register now by calling 1-866-961-2388 and help make the future better for many other
women just like you…

This study will involve 3 brief phone interviews over an 8-month period.

The National Pregnancy Registry for Atypical Antipsychotics is dedicated to evaluating the safety of atypical antipsychotic medications that may be taken by women during pregnancy to treat a wide range of mood, anxiety, or psychiatric disorders. The primary goal of this Registry is to determine the frequency of major malformations, such as heart defects, cleft lip, or neural tube defects, in infants exposed to atypical antipsychotics during pregnancy.

For more information, please call 1-866-961-2388.

Institution  –  MGH - Massachusetts General Hospital, Boston, MA; BWH - Brigham and Women's Hospital, Boston, MA; NWH, Newton, MA; Spaulding Rehab. Hospital, Boston, MA; McLean Hospital, Belmont, MA; DFCI, Boston, MA; North Shore Medical Center, Salem, MA; Beth Israel Deaconess, Boston, MA; Boston University Medical Center, Boston, MA; MIT, Cambridge, MA; Schepens Eye Research Institute, Boston, MA; Massachusetts General Hospital - East, Charlestown, MA; MGH Institute of Health Professions, Boston, MA

Principal Investigator  – Lee Cohen, MD

  

For further information about enrolling a patient in this trial, contact the person below.

Name  – Sarah Masnik

Phone  – 1-866-961-2388